bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers.
- 1 May 1997
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 133 (5) , 599-602
- https://doi.org/10.1001/archderm.1997.03890410055007
Abstract
A failure in the apoptotic response after severe genomic damage could facilitate cell transformation and tumor development, and a constitutive overexpression of either p53 or bcl-2 protein in nonapoptotic tumor cells could signify a defective bax-mediated apoptosis.Keywords
This publication has 18 references indexed in Scilit:
- Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progressionInternational Journal of Cancer, 1996
- Mechanisms and Genes of Cellular SuicideScience, 1995
- The genetic regulation of apoptosisCurrent Opinion in Genetics & Development, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- TP53 Tumor Suppressor Gene and Skin Carcinogenesis.Journal of Investigative Dermatology, 1994
- Expression of p53 protein in benign and malignant epidermal pathologic conditionsJournal of the American Academy of Dermatology, 1993
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinomaBritish Journal of Dermatology, 1992
- Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancerBritish Journal of Dermatology, 1992
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990